A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
A phase 3 trial of Giredestrant, Fulvestrant, Abemaciclib, Palbociclib and Ribociclib in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) is a phase 3 interventional study registered as NCT06065748 by Hoffmann-La Roche, with 1050 participants enrolled, started 2023-12-11 and due to reach its primary completion in 2028-04-20. Interventions recorded: Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib and LHRH Agonist.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Shares Giredestrant, Flatiron Health (Roche), Abemaciclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Shares Giredestrant, Flatiron Health (Roche), Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Shares Ribociclib, Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Shares Giredestrant, Ribociclib, Flatiron Health (Roche), Abemaciclib and the tag pipeline.
- TrialA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Shares Giredestrant, Ribociclib, Flatiron Health (Roche) and the tag pipeline.
- TrialFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.